Olanzapine Teva

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

olanzapine

Available from:

Teva B.V. 

ATC code:

N05AH03

INN (International Name):

olanzapine

Therapeutic group:

Psikolettiċi

Therapeutic area:

Schizophrenia; Bipolar Disorder

Therapeutic indications:

AdultsOlanzapine huwa indikat għall-kura ta ' skizofrenja. Olanzapine hija effettiva biex iżżomm it-titjib kliniku waqt terapija kontinwa f'pazjenti li wrew rispons inizjali għat-trattament. Olanzapine hu indikat għall-kura moderata għal severa ta ' episodju ta'manija. F'pazjenti li l-episodju ta'manija għandu rrispondew għat-trattament b'olanzapine, olanzapine hija indikata għall-prevenzjoni ta'rikorrenza f'pazjenti b'diżordni bipolari.

Product summary:

Revision: 30

Authorization status:

Awtorizzat

Authorization date:

2007-12-12

Patient Information leaflet

                                83
B. FULJETT TA’ TAGĦRIF
84
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-UTENT
OLANZAPINE TEVA 2.5 MG PILLOLI MIKSIJA B’RITA
OLANZAPINE TEVA 5 MG PILLOLI MIKSIJA B’RITA
OLANZAPINE TEVA 7.5 MG PILLOLI MIKSIJA B’RITA
OLANZAPINE TEVA 10 MG PILLOLI MIKSIJA B’RITA
OLANZAPINE TEVA 15 MG PILLOLI MIKSIJA B’RITA
OLANZAPINE TEVA 20 MG PILLOLI MIKSIJA B’RITA
olanzapine
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-ispiżjar
tiegħek.
-
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara, anke jekk għandhom l-istess sinjali ta’
mard bħal tiegħek.
-
Jekk ikollok xi effett sekondarju kellem lit-tabib jew lill-ispiżjar
tiegħek. Dan jinkludi xi effett
sekondarju possibbli li mhuwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
F’DAN IL-FULJETT
1.
X’inhu Olanzapine Teva u għalxiex tintuża
2.
X’għandek tkun taf qabel ma tieħu Olanzapine Teva
3.
Kif għandek tieħu Olanzapine Teva
4.
Effetti sekondarji possibbli
5.
Kif taħżen Olanzapine Teva
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU OLANZAPINE TEVA U GĦALXIEX JINTUŻA
Olanzapine Teva fih is-sustanza attiva olanzapine. Olanzapine Teva
jappartjeni għall-grupp ta'
mediċini msejħa antipsikotiċi u jintuża biex jittratta
l-kundizzjonijiet li ġejjin:
•
Skiżofrenija, marda b'sintomi bħal tara, tisma’ jew li tħoss
affarijiet li mhux qegħdin hemm,
twemmin żbaljat, suspetti mhux tas-soltu, u li tingħalaq fik
innifsek. Nies b'din il-marda jistgħu
wkoll iħossuhom imdejjqin, anzjużi jew taħt tensjoni.
•
Episodji ta’ manija moderati għal severi, kondizzjoni b’sintomi
ta’ eċitament jew ewforija
eċitament jew ewforija
Ġie muri li Olanvapine Teva jippreveni li dawn is-sintomi jerġgħu
jseħħu f’pazjenti bipolari, fejn
l-episodju ta’ manija rrisponda għ
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Olanzapine Teva 2.5 mg pilloli miksija b’rita
Olanzapine Teva 5 mg pilloli miksija b’rita
Olanzapine Teva 7.5 mg pilloli miksija b’rita
Olanzapine Teva 10 mg pilloli miksija b’rita
Olanzapine Teva 15-il mg pilloli miksija b’rita
Olanzapine Teva 20 mg pilloli miksija b’rita
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Olanzapine Teva 2.5 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 2.5 mg olanzapine.
_Eċċipjent b’effett magħruf _
Kull pillola miksija b’rita fiha 71.3 mg lactose.
Olanzapine Teva 5 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 5 mg olanzapine.
_Eċċipjent b’effett magħruf_
Kull pillola miksija b’rita fiha 68.9 mg lactose.
Olanzapine Teva 7.5 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 7.5 mg olanzapine.
_Eċċipjent b’effett magħruf_
Kull pillola miksija b’rita fiha 103.3 mg lactose.
Olanzapine Teva 10 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 10 mg olanzapine.
_Eċċipjent b’effett magħruf_
Kull pillola miksija b’rita fiha 137.8 mg lactose.
Olanzapine Teva 15-il mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 15-il mg olanzapine.
_Eċċipjent b’effett magħruf_
Kull pillola miksija b’rita fiha 206.7 mg lactose.
Olanzapine Teva 20 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 20 mg olanzapine.
_Eċċipjent b’effett magħruf_
Kull pillola miksija b’rita fiha 275.5 mg lactose.
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola miksija b’rita
Olanzapine Teva 2.5 mg pilloli miksija b’rita
Pilloli miksija b’rita bojod, tondi u mżaqqa li fuqhom hemm
imnaqqax “OL 2.5” fuq naħa waħda u
xejn fuq in-naħa l-oħra.
Olanzapine Teva 5 mg pilloli miksija b’rita
Pilloli miksija b’rita bojod, tondi u mżaqqa li fuqhom hemm
imnaqqax “OL 5.0” fuq naħa waħda u
xejn fuq in-naħa l-oħra.
3
Olanzapine Teva 7.5 mg pilloli miksija b
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 25-09-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 25-09-2023
Public Assessment Report Public Assessment Report Bulgarian 01-03-2013
Patient Information leaflet Patient Information leaflet Spanish 25-09-2023
Public Assessment Report Public Assessment Report Spanish 01-03-2013
Patient Information leaflet Patient Information leaflet Czech 25-09-2023
Public Assessment Report Public Assessment Report Czech 01-03-2013
Patient Information leaflet Patient Information leaflet Danish 25-09-2023
Public Assessment Report Public Assessment Report Danish 01-03-2013
Patient Information leaflet Patient Information leaflet German 25-09-2023
Public Assessment Report Public Assessment Report German 01-03-2013
Patient Information leaflet Patient Information leaflet Estonian 25-09-2023
Public Assessment Report Public Assessment Report Estonian 01-03-2013
Patient Information leaflet Patient Information leaflet Greek 25-09-2023
Public Assessment Report Public Assessment Report Greek 01-03-2013
Patient Information leaflet Patient Information leaflet English 25-09-2023
Public Assessment Report Public Assessment Report English 01-03-2013
Patient Information leaflet Patient Information leaflet French 25-09-2023
Public Assessment Report Public Assessment Report French 01-03-2013
Patient Information leaflet Patient Information leaflet Italian 25-09-2023
Public Assessment Report Public Assessment Report Italian 01-03-2013
Patient Information leaflet Patient Information leaflet Latvian 25-09-2023
Public Assessment Report Public Assessment Report Latvian 01-03-2013
Patient Information leaflet Patient Information leaflet Lithuanian 25-09-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 25-09-2023
Public Assessment Report Public Assessment Report Lithuanian 01-03-2013
Patient Information leaflet Patient Information leaflet Hungarian 25-09-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 25-09-2023
Public Assessment Report Public Assessment Report Hungarian 01-03-2013
Patient Information leaflet Patient Information leaflet Dutch 25-09-2023
Public Assessment Report Public Assessment Report Dutch 01-03-2013
Patient Information leaflet Patient Information leaflet Polish 25-09-2023
Public Assessment Report Public Assessment Report Polish 01-03-2013
Patient Information leaflet Patient Information leaflet Portuguese 25-09-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 25-09-2023
Public Assessment Report Public Assessment Report Portuguese 01-03-2013
Patient Information leaflet Patient Information leaflet Romanian 25-09-2023
Public Assessment Report Public Assessment Report Romanian 01-03-2013
Patient Information leaflet Patient Information leaflet Slovak 25-09-2023
Public Assessment Report Public Assessment Report Slovak 01-03-2013
Patient Information leaflet Patient Information leaflet Slovenian 25-09-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 25-09-2023
Public Assessment Report Public Assessment Report Slovenian 01-03-2013
Patient Information leaflet Patient Information leaflet Finnish 25-09-2023
Public Assessment Report Public Assessment Report Finnish 01-03-2013
Patient Information leaflet Patient Information leaflet Swedish 25-09-2023
Public Assessment Report Public Assessment Report Swedish 01-03-2013
Patient Information leaflet Patient Information leaflet Norwegian 25-09-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 25-09-2023
Patient Information leaflet Patient Information leaflet Icelandic 25-09-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 25-09-2023
Patient Information leaflet Patient Information leaflet Croatian 25-09-2023

Search alerts related to this product